Market capitalization | $14.46m |
Enterprise Value | $8.10m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 2.31 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-9.51m |
Free Cash Flow (TTM) Free Cash Flow | $-7.89m |
Cash position | $6.51m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Microbot Medical Inc:
1 Analyst has issued a forecast Microbot Medical Inc:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.10 -0.10 |
9%
9%
|
|
EBITDA | -9.41 -9.41 |
19%
19%
|
EBIT (Operating Income) EBIT | -9.51 -9.51 |
19%
19%
|
Net Profit | -10 -10 |
10%
10%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Microbot Medical, Inc. is a pre-clinical medical device company, which engages in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm carries out its operations through the ViRob and TipCat platforms. The ViRob platform technology is an autonomous crawling micro-robot that can be controlled remotely or within the body. It makes use of the Self-Cleaning Shunt, a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid shunt system, and is mainly used for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The TipCat platform, a self-propelling, flexible, and semi-disposable endoscope provides see-and-treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. The company was founded by Harel Gadot, Moshe Shoham, and Yosseph Bornstein on August 2, 1988 and is headquartered in Hingham, MA.
Head office | United States |
CEO | Harel Gadot |
Employees | 22 |
Founded | 1988 |
Website | microbotmedical.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.